The first Australian study to measure precision medicine costs in the care of childhood cancers

Congratulations to Luminesce Alliance lead investigator Associate Professor Ness Tyrrell and colleagues on the publication of the first Australian study to measure the cost of using precision medicine in the care of high-risk childhood cancers, through the Zero Childhood Cancer Program. The study, published in npj Precision Oncology, was supported by Luminesce Alliance ‘Economic Impact and Framework for Precision Therapy – Cancer’ project.